title: Recent advances in idiopathic pulmonary fibrosis.
abstract: The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF.
authors: Department of Internal Medicine, KEPCO Medical Center, Seoul, Korea.
authors: Sanghoon
authors: S
authors: Park
authors: Eun Joo
authors: EJ
authors: Lee
keywords: Clinical Trial; Etiology; Idiopathic Pulmonary Fibrosis
references: J Transl Med. 2011 Oct 21;9:182
references: 22017817
references: Drugs. 2011 May 28;71(8):981-1001
references: 21668038
references: N Engl J Med. 2011 Sep 22;365(12):1079-87
references: 21992121
references: Respir Res. 2011 Oct 28;12:143
references: 22035508
references: Lancet. 2011 Dec 3;378(9807):1949-61
references: 21719092
references: Am J Respir Crit Care Med. 2012 Jul 1;186(1):88-95
references: 22561965
references: Lancet. 2011 May 21;377(9779):1760-9
references: 21571362
references: Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
references: 21471066
references: Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9
references: 21474646
references: Ann Intern Med. 2012 Sep 18;157(6):398-406
references: 22986377
references: N Engl J Med. 2012 May 24;366(21):1968-77
references: 22607134
references: Lancet. 2012 Aug 18;380(9842):680-8
references: 22901889
references: Lung. 2012 Oct;190(5):523-7
references: 22810758
references: Respirology. 2012 Apr;17(3):467-77
references: 22257422